Major depression disorder (MDD) is a debilitating mental illness with significant morbidity
and mortality. Despite the growing number of studies that have emerged, the precise …

The role of the monoamines serotonin and noradrenaline in mental illnesses including
depression is well recognized. All antidepressant drugs in clinical use increase acutely the …

Anti‐inflammatory products may represent the future for depressive disorder therapies.
Curcumin (CUR) is a polyphenol and an active component of the turmeric plant Curcuma …

Macrophages and their counterparts in the central nervous system, the microglia, detect and
subsequently clear microbial pathogens and injured tissue. These phagocytic cells alter and …

For the past decade the pharmaceutical industry has experienced a steady decline in
productivity and a striking observation is that the decline coincided with the introduction of …

Major depression has been shown to increase the risk for development of epilepsy, but prior
studies have not evaluated whether this is due to specific symptoms of depression. We …

Major depression is a debilitating and recurrent disorder with a substantial lifetime risk and a
high social cost. Depressed patients generally display co-morbid symptoms, and depression …

Acupuncture, one of the most popular complementary therapies, is best known for its ability
to provide pain relief. Accumulating evidence suggests that acupuncture may also be …

We have recently shown that the hexanic extract from leaves of Schinus molle produces
antidepressant-like effects in the tail suspension test in mice. This study investigated the …

Reboxetine is the first commercially available norepinephrine reuptake inhibitor developed
specifically as a first line therapy for major depressive disorder. In vitro and in vivo …